Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 10/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.44 |
| ▸ | PDE4A | P27815 | 8/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680848 | 0.88 | PDE4D (0.54) | PDE4DKMT2APDE4BPDE4APDE4C | |
| SCHEMBL3681993 | 0.83 | PDE4D (0.50) | PDE4DMAPTTDP1KMT2APDE4B | |
| SCHEMBL335038 | 0.80 | MAPT (0.73) | MAPTTDP1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29405531 | 0.80 | MAPT (0.73) | MAPTTDP1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12760825 | 0.78 | MAPT (0.43) | PDE4DMAPTTDP1KMT2APDE4B | |
| SCHEMBL8748732 | 0.77 | KMT2A (0.52) | PDE4DMAPTTDP1KMT2APDE4B | |
| SCHEMBL12760903 | 0.77 | MAPT (0.47) | PDE4DMAPTTDP1KMT2APDE4B | |
| SCHEMBL885060 | 0.76 | PDE4D (0.83) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL730521 | 0.75 | PDE5A (0.48) | PDE4DKMT2APDE4BPDE4APDE4C | |
| SCHEMBL731158 | 0.75 | PDE5A (0.48) | PDE4DKMT2APDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745646-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080027112-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2008006051-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027112-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4D 9/4885MAPT 4437/4885TDP1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.